p53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas

Canadian Journal of Neurological Sciences

Volumn 30, Issue 3, 2003, Pages 215-219

  Hentschel, Stephen J ^a,b   McCutcheon, Ian E ^b   Moore, Wayne ^c   Durity, Felix A ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY KI 67; PROTEIN P53;

ADJUVANT THERAPY; ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HUMAN; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; TUMOR RECURRENCE;

EID: 0042363347     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100002614     Document Type: Article

References (44)

1. Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancer. Science 1991;256:49-53.
2. Pietilainen T, Lipponen P, Aaltomaa S, et al. Expression of p53 protein has no independent prognostic value in breast cancer. J Pathol 1995;177:225-232.
3. Baas I, Mulder J, Offerhaus G, et al. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994; 172:5-12.
4. Xerri L, Bouabdallah R, Camerlo J, Hassoun J. Expression of the p53 gene in Hodgkin's disease: dissociation between immunohistochemistry and clinicopathological data. Hum Pathol 1994;25:449-454.
5. Kennedy S, MacGeogh C, Jaffe R, Spurr N. Overexpression of the oncoprotein p53 in primary hepatic tumors of childhood does not correlate with gene mutations. Hum Pathol 1994;25:438-442.
6. Cho H, Ha S, Park S, et al. Role of p53 gene mutation in tumor aggressiveness of intracranial meningiomas. J Korean Med Sci 1999; 14:199-205.
7. Kyritsis A, Bondy M, Hess K, et al. Prognostic significance of p53 immunoreactivity in patients with glioma. Clin Cancer Res 1995;1:1617-1622.
8. Chozick B, Pezzullo J, Epstein M, Finch P. Prognostic implications of p53 overexpresion in supratentorial astrocytic tumors. Neurosurgery 1994;35:831-838.
9. Montine T, Bruner J, Vandersteenhoven J, et al. Prognostic significance of p53 immunoreactivity in adult patients with y supratentorial fibrillary astrocytic neoplasms. Diagn Mol Pathol 1994;3:240-245.
10. Buckley N, Bates A, Broome J, et al. p53 protein accumulates in Cushing's adenomas and invasive nonfunctional adenomas. [corrected and republished article originally printed in J Clin Endocrinol Metab 1994;79(5):1513-1516] J Clin Endocrinol Metab 1995;80:4 pages following 692.
11. Buchfelder M, Fahlbusch R, Adams E, et al. Proliferation parameters for pituitary adenomas. Acta Neurochir (Wien) 1996;65 (Suppl):18-21.
12. Thapar K, Scheithauer B, Kovacs K, et al. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 1996;38:765-771.
13. Blevins L, Verity D, Allen G. Aggressive pituitary tumours. Oncology 1998;12:1307-1315.
14. Pernicone P, Scheithauer B, Sebo T, et al. Pituitary carcinoma. Cancer 1997;79:804-812.
15. Herman V, Drazin N, Gonsky R, Melmed S. Molecular screening of pituitary adenomas for gene mutations and rearrangements. J Clin Endocrinol Metab 1993;77:50-55.
16. Perrett C, Clayton R, Pistorello M, et al. GSTM1 and CYP2D6 genotype frequencies in patients with pituitary tumours: effects on p53, ras and gsp. Carcinogenesis 1995;16:1643-1645.
17. Green V, White M, Hipkin L, et al. Apoptosis and p53 suppressor gene protein expression in human anterior pituitary adenomas. Eur J Endocrinol 1997; 136:382-387.
18. Levy A, Hall L, Yeudall W, Lightman S. p53 gene mutations in pituitary adenomas: rare events. Clin Endocrinol (Oxf) 1994;41:809-814.
19. Gandour-Edwards R, Kapadia S, Janecka I, et al. Biologic markers of invasive pituitary adenomas involving the sphenoid sinus. Mod Pathol 1995;8:160-164.
20. Litofsky N, Recht L. The impact of p53 tumor suppresor gene on glioma biology. Neurosurg Focus. 1997;3:Article 4.
21. Louis D. The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 1994;53:11-21.
22. Levine A, Momand J, Finlay C. The p53 tumor suppressor gene. Nature 1991;351:453-456.
23. Harris C, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-1327.
24. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133:1710-1715.
25. Jaros E, Perry R, Adam L, et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 1992;66:373-385.
26. Miyagami M, Nakamura S. Significance of p53 protein expression and proliferative potential with MIB-1 on tumor recurrence of pituitary adenomas. No To Shinkei 1998;50:27-32.
27. Muller W, Saeger W, Wellhausen L, et al. Markers of function and proliferation in noninvasive and invasive bi- and plurihormonal adenomas of patients with acromegaly: an immunohistochemical study. Pathol Res Pract 1999;195:595-603.
28. Thapar K, Kovacs K, Scheithauer B, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 1996;38:99-107.
29. Losa M, Frankin A, Mangili F, et al. Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results. Neurosurgery 2000;47:1313-1319.
30. Asa S, Kovacs K. Clinically nonfunctioning human pituitary adenomas. Can J Neurol Sci 1992;19:228-235.
31. Samejima N, Yamada S, Takada K, et al. Serum α-subunit levels in patients with pituitary adenomas. Clin Endocrinol (Oxf) 2001;54:479-484.
32. Ciric I, Mikhael M, Stafford T, et al. Transsphenoidal microsurgery of pituitary macroadenomas with long-term follow-up results. J Neurosurg 1983;59:395-401.
33. Gee J, Douglas-Jones A, Hepburn P, et al. A cautionary note regarding the application of Ki-67 antibodies to paraffin-embedded breast cancers. J Pathol 1995;177:285-293.
34. Pegolo G, Buckwalter J, Weiss M. Pituitary adenomas: correlation of the cytologic appearance with biologic behavior. Acta Cytol 1995;39:887-892.
35. Knosp E, Kitz K, Perneczky A. Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery 1989;25:927-930.
36. Ebersold M, Quast L, ER Laws J, et al. Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas. J Neurosurg 1986;64:713-719.
37. Scheithauer B, Kovacs K, ER Laws J, Randall R. Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 1986;65:733-744.
38. Selman W, ER Laws J, Scheithauer B, Carpenter S. The occurence of dural invasion in pituitary adenomas. J Neurosurg 1986;64:402-407.
39. Sautner D, Saeger W. Invasiveness of pituitary adenomas. Pathol Res Pract 1991;187:632-636.
40. Mindermann T, Wilson C. Thyrotropin-producing pituitary adenomas. J Neurosurg 1993;79:521-527.
41. Fahlbusch R, Honneger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin North Am 1992;21:669-692.
42. Yonezawa K, Tamaki N, Kokunai T. Clinical features and growth fractions of pituitary adenomas. Surg Neurol 1997;48:494-500.
43. Battifora H. p53 immunohistochemistry: a word of caution. Hum Pathol 1994;25:435-436.
44. Clayton R, Boggild M, Bates A, et al. Tumour suppressor genes in the pathogenesis of human pituitary tumours. Horm Res 1997;47:185-193.